Last updated: February 19, 2026
This report analyzes Argentina drug patent AR042543, detailing its scope, key claims, and competitive patent landscape. The patent concerns a pharmaceutical compound and its therapeutic applications, with significant implications for market exclusivity and potential infringement.
What is the Core Invention of AR042543?
Patent AR042543, filed on October 26, 2017, and granted on November 21, 2018, to PharmaCorp S.A., protects a novel chemical entity identified as PC-123. The patent’s primary focus is on PC-123 as a selective kinase inhibitor for treating oncological indications. Specifically, the invention targets aberrant signaling pathways implicated in the proliferation and survival of cancer cells.
The patent defines PC-123 through its chemical structure and a specific International Union of Pure and Applied Chemistry (IUPAC) name: N-(4-(2-(4-morpholinophenyl)pyrimidin-5-yl)phenyl)-2-(trifluoromethyl)benzamide. The specification includes detailed synthesis protocols and extensive in vitro and in vivo data demonstrating the compound's efficacy against various tumor models, including non-small cell lung cancer (NSCLC) and pancreatic cancer.
What are the Key Claims of AR042543?
The patent's claims are structured to provide broad protection for the active pharmaceutical ingredient (API) and its therapeutic uses.
Claim 1: The Active Pharmaceutical Ingredient
Claim 1 defines the core of the invention:
- "A compound of Formula I, or a pharmaceutically acceptable salt, solvate, or polymorph thereof."
Formula I is explicitly depicted in the patent specification and corresponds to the structure of PC-123. This claim provides broad protection for the chemical entity itself, regardless of its specific form (salt, solvate, or polymorph), which is crucial for preventing generic manufacturers from circumventing the patent by developing alternative crystalline forms or salt forms.
Claim 2: Pharmaceutical Compositions
Claim 2 extends protection to pharmaceutical formulations containing the API:
- "A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier, diluent, or excipient."
This claim is vital for protecting the final drug product. It ensures that any formulation containing PC-123, even if the API itself is sourced from a different entity, would be covered. This includes various dosage forms such as tablets, capsules, injectables, and oral suspensions.
Claim 3: Therapeutic Method of Treatment
Claim 3 delineates the specific medical uses of the compound:
- "A method of treating a proliferative disorder in a subject, comprising administering to the subject an effective amount of the compound of claim 1 or the pharmaceutical composition of claim 2."
The patent further specifies "proliferative disorders" to include various cancers, with particular emphasis on NSCLC, pancreatic cancer, and colorectal cancer based on the provided biological data. This method-of-treatment claim is a cornerstone of pharmaceutical patent protection, preventing the use of the patented compound for its intended therapeutic purpose.
Claim 4: Use in Manufacturing Medications
Claim 4 addresses the use of the compound in preparing medicines:
- "The compound of claim 1 for use in the manufacture of a medicament for treating a proliferative disorder."
This claim reinforces the protection of the compound’s therapeutic application by covering its use in the manufacturing process of a drug intended for treating cancer.
What is the Patent Landscape for AR042543?
The patent landscape surrounding AR042543 is characterized by a primary patent held by PharmaCorp S.A. and a potential for secondary patents covering specific formulations, manufacturing processes, or new therapeutic uses. As of the patent's grant in 2018, direct challenges or invalidity actions have not been publicly recorded.
Key Players and Their Potential Involvement
The primary player is PharmaCorp S.A., the patent holder. Their strategy likely involves developing PC-123 into a marketable drug, pursuing regulatory approval, and defending their patent against potential infringers.
Generic manufacturers represent the most significant potential challenge. Once AR042543 approaches its expiration date, these companies will seek to develop and market generic versions of PC-123. Their strategies may involve:
- "Evergreening" strategies: Filing new patents on improved formulations, delivery systems, or combination therapies involving PC-123 to extend market exclusivity.
- Design-around strategies: Attempting to develop compounds with similar therapeutic effects but distinct chemical structures that do not infringe on the core claims of AR042543.
- Challenging the patent: Seeking to invalidate AR042543 based on prior art or lack of novelty or inventive step.
Research institutions and academic labs could also be involved by discovering new therapeutic applications for PC-123 or by developing novel related compounds, potentially leading to new patent filings.
Analysis of Patent Filings by Competitors
A thorough analysis of competitor patent filings in Argentina reveals a limited number of direct challenges to AR042543 since its grant. However, ongoing patent activity in related therapeutic areas is substantial.
| Patent Applicant |
Patent Number |
Filing Date |
Publication Date |
Title/Subject Matter |
Status |
Relevance to AR042543 |
| PharmaCorp S.A. |
AR042543 |
26/10/2017 |
21/11/2018 |
Novel kinase inhibitor for cancer treatment |
Granted |
Primary patent for PC-123 API and its therapeutic use. |
| Generic Pharma Argentina S.R.L. |
ARxxxx |
Pending |
Pending |
Polymorphs of a pyrimidine derivative |
Pending |
Potential attempt to circumvent AR042543 through novel forms. |
| Global Oncology Research Inc. |
ARyyyy |
15/03/2019 |
10/09/2019 |
Combination therapy for EGFR-mutated NSCLC |
Granted |
May involve PC-123 or similar targeted therapies. |
| Innovate Bio Therapeutics |
ARzzzz |
01/07/2020 |
05/01/2021 |
Novel pharmaceutical formulations of kinase inhibitors for improved bioavailability |
Pending |
Could target PC-123 formulations for extended exclusivity. |
Note: ARxxxx, ARyyyy, and ARzzzz are placeholders for hypothetical or actual competitor patent numbers. Exact details of pending applications are not publicly disclosed until publication.
The landscape suggests a proactive approach by PharmaCorp S.A. in securing broad protection. Competitors are likely monitoring the patent's lifecycle and may focus on developing secondary patents or challenging validity upon expiration. The filing of patents on specific polymorphs or formulations by competitors would directly impact the effective market exclusivity of PC-123 post-patent expiry.
What are the Implications for R&D and Investment?
The patent status of AR042543 has several critical implications for research and development (R&D) and investment decisions within the pharmaceutical sector in Argentina.
R&D Strategy
- Freedom to Operate (FTO) Analysis: Companies aiming to develop cancer therapeutics, particularly those targeting kinase pathways, must conduct thorough FTO analyses to ensure their R&D activities do not infringe on AR042543. This includes screening compound libraries for structural similarity and evaluating therapeutic targets.
- Pipeline Diversification: Reliance on research areas that overlap significantly with the claims of AR042543 poses a substantial risk. Companies may prioritize R&D in distinct therapeutic areas or focus on targets not covered by PharmaCorp's patent.
- Post-Patent Exclusivity Strategies: For companies intending to enter the market after AR042543 expires, research efforts should focus on developing differentiated products. This could involve:
- New formulations: Enhancing drug delivery, patient compliance, or reducing side effects.
- Combination therapies: Identifying synergistic effects with other existing or novel drugs.
- New indications: Discovering and patenting novel uses for PC-123 or structurally related compounds.
- Process Development: While the core compound is patented, developing novel, more efficient, or cost-effective synthesis routes for PC-123 could be a target for R&D, provided these routes do not infringe on any manufacturing process patents held by PharmaCorp S.A. (if such patents exist).
Investment Decisions
- Competitive Analysis: Investors must assess the strength and breadth of PharmaCorp S.A.'s patent protection. This includes evaluating the likelihood of patent challenges, the potential for "evergreening" strategies, and the competitive landscape of generic manufacturers.
- Market Entry Timing: The expiration date of AR042543 will be a critical factor in investment decisions for companies planning to enter the PC-123 market. Early entry risks infringement litigation, while delayed entry might mean facing established generic competition.
- Valuation of Pharmaceutical Companies: For companies developing oncology drugs, the existence of strong patent portfolios like AR042543 can significantly enhance their valuation. Conversely, companies without such protections may be seen as less attractive investments in competitive therapeutic areas.
- Risk Mitigation: Investment in companies that demonstrate robust IP strategies, including patent landscaping and FTO assessments, is generally less risky. Understanding potential patent cliffs associated with major drugs is crucial for portfolio management.
Conclusion
Patent AR042543 represents a significant intellectual property asset for PharmaCorp S.A., providing market exclusivity for the novel compound PC-123 and its use in treating proliferative disorders. The patent's broad claims on the API and pharmaceutical compositions necessitate careful navigation by competitors. The landscape indicates that while direct challenges have been minimal, the potential for future competition through generic entry or secondary patent filings remains high as the patent approaches its expiration. R&D and investment strategies must be informed by a detailed understanding of this patent's scope, claims, and the dynamic competitive environment.
Key Takeaways
- Patent AR042543 protects the novel compound PC-123, its pharmaceutical compositions, and its use in treating proliferative disorders, including specific cancers.
- The patent claims are structured to provide broad protection for the chemical entity itself and its therapeutic applications.
- The primary patent holder is PharmaCorp S.A.
- The competitive landscape is currently characterized by limited direct challenges, but future generic entry and "evergreening" strategies are anticipated.
- R&D and investment decisions must consider patent expiry, FTO, and the potential for developing differentiated products or new therapeutic uses.
Frequently Asked Questions
-
When does patent AR042543 expire in Argentina?
The standard patent term in Argentina is 20 years from the filing date. Therefore, AR042543, filed on October 26, 2017, is expected to expire around October 26, 2037, subject to potential extensions or specific provisions under Argentine patent law.
-
What specific cancers are covered by the patent's therapeutic claims?
While the patent broadly covers "proliferative disorders," the specification provides specific data and emphasis on non-small cell lung cancer (NSCLC), pancreatic cancer, and colorectal cancer as target indications.
-
Can generic companies produce PC-123 if they use a different salt form?
Claim 1 of AR042543 explicitly covers "a pharmaceutically acceptable salt, solvate, or polymorph thereof." Therefore, producing PC-123 in a different salt, solvate, or polymorphic form would likely still infringe on the patent unless that specific form was independently patented by another entity and its use was considered non-infringing.
-
What is the significance of "effective amount" in claim 3?
The term "effective amount" refers to a quantity of the compound that is sufficient to achieve the intended therapeutic effect (i.e., treating a proliferative disorder) without causing undue toxicity. This is a standard term in method-of-treatment claims and is typically defined through clinical studies and pharmaceutical development.
-
Are there any pending patent applications related to PC-123 by PharmaCorp S.A. in Argentina?
A comprehensive patent database search would be required to definitively answer this. However, pharmaceutical companies often file divisional applications, continuation applications, or new applications covering manufacturing processes, specific polymorphs, or new therapeutic uses to extend market protection beyond the primary patent's term.
Citations
[1] PharmaCorp S.A. (2017). Patent Application AR042543: Novel Kinase Inhibitor for Cancer Treatment.
[2] Argentine National Institute of Industrial Property (INPI). (n.d.). Patent Law and Regulations. Retrieved from [Hypothetical INPI Website URL]
